Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases

BioPharma Dive

Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.

M&A / DealsImmunology & InflammationRead full story